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To the Editor
Concerns have been raised about adverse health effects from ubiquitous exposure during 
pregnancy to phthalates and phenols. Toxicologic data suggest that some of these 
compounds can disrupt the hormonal signaling that regulates male genital organogenesis. 
Evidence from the epidemiologic literature assessing association between in utero exposure 
to these compounds and male genital anomalies is limited and inconclusive.1–3
We evaluated whether prenatal exposure to select phthalates and phenols was associated 
with occurrence of hypospadias and undescended testes in a case-control study (eTable 1, 
http://links.lww.com/EDE/A558) nested in the EDEN and PELAGIE mother–child cohorts 
(5200 pregnant women).4 Cases of hypospadias (n = 21) and undescended testis (unilateral 
or bilateral, not in scrotum, n = 50) were identified during the first days after birth by 
pediatricians or midwives. Three controls per case were selected among male singleton live 
births, matched with cases for residence area, gestational age at urine sample collection, and 
date and day of collection (Sunday–Monday vs. other). Urinary concentrations of 11 
phthalate metabolites and 9 phenols (samples collected in the morning, eTable 2, http://
links.lww.com/EDE/A558), determined without knowledge of case-control status, were 
standardized by sampling conditions that varied among participants using a 2-step 
standardization method based on regression residuals as described previously.4 As an 
alternative exposure metric, we used a specific job-exposure matrix (JEM).2,3
In all, 13 women (9%) were classified as possibly exposed to phthalates in the workplace. 
No correlation between occupational exposure to phthalates and the urinary concentrations 
of phthalate metabolites was seen (eTable3, http://links.lww.com/EDE/A558). Due to the 
short-lived nature of these compounds, the morning urinary biomarkers do not necessarily 
capture occupational exposures, such that both exposure metrics might reflect 
complementary exposure sources. Using conditional logistic regression, we observed 
slightly reduced risks of hypospadias with increasing urinary concentrations of all phthalate 
metabolites (Table, eTable4, http://links.lww.com/EDE/A558). Increased risk of 
undescended testis was observed in association with the second or third tertiles of urinary 
concentrations of bisphenol A (BPA), 2,4-dichlorophenol, and ethylparaben compared with 
the first tertile (Table); increases were more pronounced among term boys (eTable5, http://
links.lww.com/EDE/A558). The odds ratio (OR) for hypospadias associated with possible 
maternal occupational exposure to phthalates was 4.2 (95% confidence interval [CI] 0.4–
41.3; 2 exposed cases and 2 exposed matched controls), whereas the OR for undescended 
testes was 0.3 (0.0–3.1; 1 exposed case and 6 exposed matched controls). A possible role of 
co-occurring compounds in the corresponding occupations (n = 9 hairdressers in our study) 
cannot be discarded.
The main limitation of our study was the modest sample size, especially for results 
concerning phenols (available only in the EDEN cohort). Despite consistency with their 
estrogenic molecular activity, findings reported for phenols are subject to special caution 
because they are not supported by animal data. The use of a single spot urine sample may 
not efficiently reflect the average level of weekly or monthly exposure for compounds such 
as di(2-ethylhexyl) phthalate (DEHP) and BPA with an important dietary pathway,5–7 but it 
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provides reliable exposure measures for low-molecular-weight phthalates and parabens, 
likely due to regular use of personal-care products.5,7
Our prospective study did not show evidence of increased risks of male genital anomalies 
with prenatal exposure to phthalates. We did not confirm the inverse relation between 
prenatal DEHP exposure and testicular descent (assessed at approximately 1 year old) 
previously suggested by a study relying on 12 cases1; both the earlier study and our study 
found no increased risk for other phthalates.1 In contrast, we observed an unexpected 
decrease in the risk of hypospadias with increased concentrations of maternal urinary 
phthalate metabolites, for which we have no clear explanation. We speculate on a possible 
role of PPAR (peroxisome proliferator-activated receptors) ligands (known for some 
phthalates) and its critical role in placenta development, as previously proposed.8
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